Sabag Mark 4

What Happened

• Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries (TEVA), received an award of 141,478 restricted share units (RSUs) on 2026-01-27. The Form 4 reports the acquisition as a derivative award (transaction code A) with an acquisition price of $0.00 — typical for equity awards where no cash purchase was made.

Key Details

• Transaction date: January 27, 2026; Form filed Jan 29, 2026 (appears timely).
• Award: 141,478 restricted share units; reported price $0.00 (derivative equity award).
• Vesting/conditions: These RSUs were converted from performance share units after performance criteria were met; they remain subject to time-based vesting and will vest on March 3, 2026 (footnote).
• Settlement: Each RSU represents a contingent right to receive one ordinary share (or, at the committee’s option, cash) and ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share) (footnotes).
• Shares owned after transaction: Not specified in the filing.

Context

• This is a grant/award (not a purchase or sale) tied to performance and time-based vesting; it does not represent an immediate cash outlay or open-market purchase by the insider. Such awards are common for executive compensation and become more informative once vested or settled.